Nation: UAE, Israel in stem cell research pact
ADSSC-Pluristem collaborate involves exchange of data and expertise
The Abu Dhabi Stem Cells Centre (ADSSC) has signed a Memorandum of Understanding with Israel’s Pluristem Therapeutics to collaborate on research related to regenerative medicine, including those that can be used to combat the pandemic.
The agreement was signed by Emirati and Israeli representatives of the companies during a videoconference.
The aim of the collaboration is to capitalise on each company’s
The UAE has always been inclusive in its approach to finding solutions to global challenges, bringing together the many competencies of people from diverse countries.”
Dr Fatima Al Kaabi | Executive director of the Abu Dhabi Bone Marrow Transplant programme
respective areas of expertise in cell therapies.
Innovative products
Both ADSCC and Pluristem have developed innovative products related to Covid-19 treatment. Pluristem’s placental PLX-PAD allogeneic product is currently in phase II studies in the US and EU.
ADSCC’s UAECell19 product has shown, relative to standard treatment, clinical improvement in half the usual time and reduction in the length of hospital stays to about a quarter of the average duration.
“The UAE has always been inclusive in its approach to finding solutions to global challenges, bringing together the many competencies of people from diverse countries,” said Dr Fatima Al Kaabi, executive director of the Abu Dhabi Bone Marrow Transplant programme. “We at ADSCC have followed suit, as is evident in the diversity of expertise among my colleagues and our international partners.”
Both companies will exchange research results, share samples, join usage of equipment and testing, and other essential activities related to advancing the treatment and research of cell therapies.
‘Bridge to build peace’
Yaki Yanai, CEO and president of Pluristem, said: “We see life science and regenerative medicine as a bridge for building peace, prosperity, and well-being in our region and for the entire world.
“I believe it is our obligation and privilege as business and scientific leaders to lead the way forward to strengthen collaborations, and promote innovation and education.”